SCHEMBL3569039

SCHEMBL3569039

COCNC(=O)c1csc(Br)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.52
HDAC6 Q9UBN7 6/20 0.52
HDAC8 Q9BY41 5/20 0.52
HDAC3 O15379 3/20 0.52
HDAC2 Q92769 2/20 0.52
HDAC4 P56524 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
CYP1A2 P05177 4/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2C9 P11712 4/20 0.42
CYP2C19 P33261 4/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HIF1A Q16665 1/20 0.40
HPGDS O60760 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3818165 0.83 MAPT (0.51) CYP1A2CYP3A4CYP2C9CYP2C19POLB
SCHEMBL25339470 0.79 HDAC1 (0.53) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3436865 0.79 HDAC3 (0.61) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL2895782 0.78 HDAC1 (0.64) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL27038851 0.77 HDAC1 (0.52) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL722692 0.77 HPGD (0.64) HDAC1HDAC6HDAC8CYP1A2CYP3A4
SCHEMBL27187309 0.77 HDAC3 (0.70) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL27187336 0.76 HDAC3 (0.72) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL27187315 0.76 HDAC3 (0.72) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL27187326 0.76 HDAC3 (0.72) HDAC1HDAC6HDAC8HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262035-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2018-01-03 EP disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 HDAC1 2786/4885HDAC6 4033/4885HDAC8 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.